Cerebrospinal fluid camk2a levels at baseline predict long-term progression in multiple sclerosis

Area of Science:

• Neuroscience
• Biomarker Discovery
• Clinical Proteomics

Background:

• Multiple sclerosis (MS) is a complex neurological disorder with unpredictable disease trajectories.
• Identifying reliable fluid biomarkers is crucial for disease stratification and personalized treatment strategies in MS.
• Cerebrospinal fluid (CSF) biomarkers hold potential for predicting long-term clinical outcomes in MS patients.

Purpose of the Study:

• To assess the predictive capability of CSF brain-specific proteins in early-stage multiple sclerosis.
• To correlate protein concentrations with long-term clinical disease progression over at least 15 years.
• To identify novel CSF biomarkers for improved MS patient management.

Main Methods:

• Analysis of CSF samples from 34 MS patients within 5 years of disease onset.
• Quantification of 64 brain-specific proteins using targeted liquid-chromatography tandem mass spectrometry.
• Clinical follow-up of patients for a minimum of 15 years, alongside analysis of 19 control samples.

Main Results:

• Six CSF proteins significantly distinguished MS patients from healthy controls (p < 0.05).
• Nine identified proteins demonstrated predictive value for disease course over the subsequent decade.
• CAMK2A emerged as a key biomarker, differentiating MS from controls and predicting long-term progression.

Conclusions:

• Targeted CSF proteomic analysis can identify biomarkers informing long-term multiple sclerosis outcomes.
• CAMK2A is a promising candidate biomarker for MS progression, requiring further investigation.
• These findings support the development of CSF-based predictive tools for personalized MS care.